Doing Well by Doing Good
At Regeneron, we believe in "doing well by doing good." We not only work to invent new and needed medicines; we also are focused on improving our world and operating with the highest standards of integrity. We are proud not only of what we do, but how we do it.
Science, Technology, Engineering and Math (STEM) education is at the heart of our corporate citizenship efforts, representing more than 90 percent of our citizenship investments. We are deeply committed to supporting the development of highly engaged, well-trained, and innovative young thinkers.
We focus on programs that support, challenge and reward the best and brightest minds in science research, increase the effectiveness of teachers in STEM and bridge STEM skills gaps and career awareness among students historically underrepresented in the sciences.
A long-standing commitment to science education
- - Science Research Mentorship Program
- - Westchester Science & Engineering Fair
- - College Internship Program
- - Postdoctoral Fellowship
- - Regeneron Prize for Creative Innovation
- - Society for Science & the Public Science News in High Schools
- - STEM Teaching Fellowship
- - BioBus
- - Sci2Med Academy
Regeneron is a leading science and technology company delivering life-transforming medicines for serious diseases. Founded by physician-scientists nearly 30 years ago, our science-focused approach has resulted in four FDA-approved medicines, and numerous product candidates to treat cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases.
The discovery and development of our medicines was enabled by our groundbreaking VelociSuite® genetic and antibody technology platforms. We are also home to the Regeneron Genetics Center – one of the world’s largest, integrated programs of its kind.
We harness the power of science to transform lives.
REGENERON BY THE NUMBERS
an MD, PhD, or
Ranked #1 or #2 employer in the global
biopharmaceutical industry in Science
Top Employers Survey 5 years in a row
volunteer hours at 66
Regeneron in the
of drug candidates
sequenced by the
Regeneron Genetics Center
antibodies in clinical
trials across multiple
- Fortune: Best Companies to Work For, 2016
Barron's: World's Best CEOs, 2016
Crain's New York Business: Fast 50, 2015
Science: Top Employer, 2015
- Forbes: World's Most Innovative Companies, 2015
Shingo Prize: Operational Excellence, 2013
Scrip Award: Clinical Advance of the Year, 2013
Scrip Award: Management Team of the Year, 2013
Regeneron is led by two physician-scientists, who, remarkably, are both alumni of the STS competition.
Leonard S. Schleifer, MD, PhD, Founder, President, CEO and 1970 STS semifinalist, founded the company in 1988 while serving as an Assistant Professor of Neurology at Weill Cornell Medical College.
He quickly approached George Yancopoulos, MD, PhD, a 28-year-old Professor of Biology at Columbia University, to join him in the new endeavor. The son of Greek immigrants, George had been driven to succeed in science his whole life and was also a top STS winner in 1976 while attending the Bronx High School of Science. Like Len, he grew up in Queens, New York, but the two had never met. In 1989, George joined the company as Founding Scientist and President of Regeneron Laboratories. He later became a member of the National Academy of Sciences, which is virtually unheard of for an industry scientist, and was the 11th most highly cited scientist in the world in the 1990s.
Leveraging a lifelong passion for science and an entrepreneurial spirit, Len and George were able to secure $1 million in venture funding from Merrill Lynch. Recognizing the critical value of scientific mentorship and expertise, they began recruiting top scientists to serve as company advisors, including multiple Nobel Prize winners to join the Board of Directors.
In 1995, Len and George approached one such scientific luminary, Roy Vagelos, MD, who was retiring as Merck CEO and Chairman, to join Regeneron as Chairman of the Board. One of the most respected leaders in science and business, Roy had built Merck into a scientific and drug development powerhouse, and just as importantly, set a new standard in corporate citizenship. During Roy's tenure, Merck was named the most trusted company in America.
The company benefits from one of the longest-standing and distinguished Board of Directors, including two Nobel Laureates and six members of the National Academy of Sciences. Demonstrating the company's commitment to scientific excellence, Regeneron was one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice that has since become industry standard.
WE WERE ONCE A SMALL COMPANY WITH BIG IDEAS.
THE ONLY THING THAT'S CHANGED IS OUR SIZE.
Regeneron is founded by Leonard S. Schleifer, MD, PhD,
young neurologist and assistant professor at Cornell University Medical College
George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, joins Regeneron as Founding Scientist, and becomes the 11th most highly cited scientist in the world during the 1990s
Science publishes first Regeneron paper, which becomes the most highly cited neurobiology paper of the year; company announces collaboration to develop neurotrophic factors
First paper on VelociGene® is published, introducing the world to proprietary Veloci technologies;
Regeneron becomes one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students
Sarilumab, our first fully human antibody, enters clinical development;
Collaboration with Bayer HealthCare focuses on developing EYLEA® (aflibercept) Injection outside the U.S.
Regeneron begins a collaboration with Sanofi focused on developing fully human antibodies
using our VelocImmune® technology platform
FDA approves ARCALYST® (rilonacept) Injection
Regeneron begins sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in under-served school districts
Our President and CEO, Leonard S. Schleifer, is named Ernst & Young Entrepreneur Of The Year® 2011 New York Award Winner; FDA approves EYLEA® (aflibercept) Injection for a blindness-causing disease
Science Top Employer survey names Regeneron #1 employer in the global biopharmaceutical industry;
Scrip Intelligence names us Biotech Company of the Year
Regeneron launches and announces the first recipients of our annual "Regeneron Prize for Creative Innovation"; European business office opens in Dublin, Ireland; Scrip Intelligence names CEO and CSO "Management Team of the Year"
Regeneron launches the Regeneron Genetics Center, a new human genetics initiative; Launches STEM Teaching Fellowship, a joint effort with the STEM Leadership Center to develop a highly trained science teacher community; Launches Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields; FDA grants investigational antibody dupilumab a Breakthrough Therapy designation; Regeneron begins planning first ex-U.S. IOPS site in Limerick, Ireland
Top Employers Survey ranks us #1 or #2 employer in the global biopharmaceutical industry 5 years in a row; FDA approves PRALUENT® (alirocumab) Injection, our fourth FDA-approved medicine and first fully human monoclonal antibody; Regeneron enters into an agreement with the U.S. government for the development of a new antibody treatment for the Ebola virus; Regeneron launches a major new immuno-oncology collaboration with Sanofi
FDA accepts our Biologics License Application for the review and potential approval of sarilumab
OUR LEGACY WITH STS
We are proud to have several STS alumni among our employee base, including Leonard S. Schleifer, MD, PhD, our Founder, President and Chief Executive Officer, and George Yancopoulos, MD, PhD, our Founding Scientist, President of Regeneron Laboratories and Chief Scientific Officer.